What are Genmab's actual plans for drug hope?
Genmab will soon be forced to reveal what the company’s actual plans for cancer drug, daratumumab, are, says an analyst from Jyske Bank. He is holding his breath for three near-term announcements.
by Leonora Beck
On Tuesday morning, Genmab announced that they would be initiating a phase II study with daratumumab for the treatment of myelomatosis. A good - but by no means surprising - announcement, says analyst Frank Hørning Andersen, Jyske Bank. But he calls for information concerning what the Danish biotech and its Belgian-American partner, Janssen, really have planned with daratumumab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
